Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the sale, the insider now owns 42,246 shares in the company, valued at $1,901,070. The trade was a 6.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total transaction of $224,250.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total value of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00.

RxSight Price Performance

Shares of RXST stock opened at $44.81 on Thursday. The business’s 50-day moving average price is $49.78 and its 200-day moving average price is $52.98. RxSight, Inc. has a 12 month low of $27.51 and a 12 month high of $66.54.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Oppenheimer cut their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Jefferies Financial Group initiated coverage on RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Finally, Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $61.63.

Hedge Funds Weigh In On RxSight

Large investors have recently modified their holdings of the business. CWM LLC boosted its holdings in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after acquiring an additional 371 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after purchasing an additional 521 shares during the last quarter. Quarry LP increased its position in shares of RxSight by 82.3% during the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after buying an additional 288 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of RxSight during the third quarter worth $34,000. Finally, Quest Partners LLC bought a new position in RxSight during the second quarter worth $41,000. Institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.